The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.
{iframe}https://medcitynews.com/2019/01/industry-execs-forecast-the-year-ahead-for-gene-therapy-at-biotech-showcase/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=68817132&_hsenc=p2ANqtz-_gYPDvdKSNA_JTRgHAyNQAOhTUF09ZMZoS-x2uGiXJEXxbfBDwKTP9DxAZsbqz45zPsPGz4urPAiGrE3qsHZkqnP_A3A&_hsmi=68817132{/iframe}